Skip to main content
. 2021 Jun 8;11:641833. doi: 10.3389/fonc.2021.641833

Figure 1.

Figure 1

DUXAP9 was upregulated in renal cancer and predicted poor prognosis in localized ccRCC patients. (A) Relative DUXAP9 expression levels in 112 pairs of localized ccRCC and matched adjacent non-tumor tissues from the SYSUCC Biobank, as detected by qRT-PCR. (B) Optimal cutoff to divide ccRCC patients into high and low DUXAP9 expression groups, as determined by X-tile bioinformatics software based on the integral optic density. (C, D) Kaplan–Meier curves showing that high DUXAP9 expression (n=19) in localized ccRCC tissues was significantly associated with poor OS and PFS rates, compared with low expression (n=93). (E) Relative DUXAP9 expression levels in renal cancer cell lines, as detected by qRT-PCR. (F) FISH analysis of the subcellular distribution of DUXAP9 in Umrc6. (G) Subcellular fractionation and qRT-PCR analyses of DUXAP9 expression in the nucleus and cytoplasm. Data represent mean ± SD from three independent experiments. ccRCC, clear cell renal cell carcinoma; qRT-PCR, quantitative real-time PCR; OS, overall survival; PFS, progression-free survival; FISH, fluorescence in situ hybridization.